Neoadjuvant radioimmunotherapy synergy in triple-negative breast cancer: Is microenvironment-guided patient selection on the horizon?

Simona F. Shaitelman; Wendy A. Woodward

doi:10.1016/j.ccell.2023.12.009

Neoadjuvant radioimmunotherapy synergy in triple-negative breast cancer: Is microenvironment-guided patient selection on the horizon?

Simona F. Shaitelman, Wendy A. Woodward

Breast Radiation Oncology

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Neoadjuvant chemotherapy plus immunotherapy for triple-negative breast cancer (TNBC) is associated with improved but incomplete response. In this issue of Cancer Cell, Shiao et al. characterize longitudinal biopsies from a window of opportunity study with single-cell RNA sequencing (scRNA-seq) and spatial proteomic profiling and elucidate synergy between radiotherapy (RT) and pembrolizumab.

Original language	English (US)
Pages (from-to)	10-12
Number of pages	3
Journal	Cancer cell
Volume	42
Issue number	1
DOIs	https://doi.org/10.1016/j.ccell.2023.12.009
State	Published - Jan 8 2024

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/j.ccell.2023.12.009

Cite this

@article{4da4425037cf4e9c8e16db4008869cbe,

title = "Neoadjuvant radioimmunotherapy synergy in triple-negative breast cancer: Is microenvironment-guided patient selection on the horizon?",

abstract = "Neoadjuvant chemotherapy plus immunotherapy for triple-negative breast cancer (TNBC) is associated with improved but incomplete response. In this issue of Cancer Cell, Shiao et al. characterize longitudinal biopsies from a window of opportunity study with single-cell RNA sequencing (scRNA-seq) and spatial proteomic profiling and elucidate synergy between radiotherapy (RT) and pembrolizumab.",

author = "Shaitelman, {Simona F.} and Woodward, {Wendy A.}",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",

year = "2024",

month = jan,

day = "8",

doi = "10.1016/j.ccell.2023.12.009",

language = "English (US)",

volume = "42",

pages = "10--12",

journal = "Cancer cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - Neoadjuvant radioimmunotherapy synergy in triple-negative breast cancer

T2 - Is microenvironment-guided patient selection on the horizon?

AU - Shaitelman, Simona F.

AU - Woodward, Wendy A.

PY - 2024/1/8

Y1 - 2024/1/8

N2 - Neoadjuvant chemotherapy plus immunotherapy for triple-negative breast cancer (TNBC) is associated with improved but incomplete response. In this issue of Cancer Cell, Shiao et al. characterize longitudinal biopsies from a window of opportunity study with single-cell RNA sequencing (scRNA-seq) and spatial proteomic profiling and elucidate synergy between radiotherapy (RT) and pembrolizumab.

AB - Neoadjuvant chemotherapy plus immunotherapy for triple-negative breast cancer (TNBC) is associated with improved but incomplete response. In this issue of Cancer Cell, Shiao et al. characterize longitudinal biopsies from a window of opportunity study with single-cell RNA sequencing (scRNA-seq) and spatial proteomic profiling and elucidate synergy between radiotherapy (RT) and pembrolizumab.

UR - http://www.scopus.com/inward/record.url?scp=85181805537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85181805537&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2023.12.009

DO - 10.1016/j.ccell.2023.12.009

M3 - Comment/debate

C2 - 38194911

AN - SCOPUS:85181805537

SN - 1535-6108

VL - 42

SP - 10

EP - 12

JO - Cancer cell

JF - Cancer cell

IS - 1

ER -

Neoadjuvant radioimmunotherapy synergy in triple-negative breast cancer: Is microenvironment-guided patient selection on the horizon?

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this